Symbol="IMTX"
AssetType="Common Stock"
Name="Immatics NV"
Description="Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in the United States. The company is headquartered in Tbingen, Germany."
CIK="1809196"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="PAUL EHRLICH-STRASSE 15, TUBINGEN, DE"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="980186000"
EBITDA="-61604000"
PERatio="None"
PEGRatio="None"
BookValue="2.61"
DividendPerShare="0"
DividendYield="0"
EPS="-1.19"
RevenuePerShareTTM="1.128"
ProfitMargin="-0.852"
OperatingMarginTTM="-0.815"
ReturnOnAssetsTTM="-0.123"
ReturnOnEquityTTM="-0.43"
RevenueTTM="79720000"
GrossProfitTTM="172831000"
DilutedEPSTTM="-1.19"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.905"
AnalystTargetPrice="17.89"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4.703"
PriceToBookRatio="6.18"
EVToRevenue="2.833"
EVToEBITDA="9.92"
Beta="0.5"
num_52WeekHigh="13.6"
num_52WeekLow="5.9"
num_50DayMovingAverage="11.19"
num_200DayMovingAverage="9.49"
SharesOutstanding="76672000"
DividendDate="None"
ExDividendDate="None"
symbol="IMTX"
open="11.56"
high="12.20"
low="11.42"
price="12.13"
volume="409671.00"
latest_trading_day="2023-07-28"
previous_close="11.45"
change="0.68"
change_percent="5.9389%"
aroon_positive_momentum_days="61"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="61"
Volume_recent_avg="429319"
Change_recent_avg="-0.01"
Delta_recent_avg="0.54"
Variance_recent_avg="0.27"
Change_ratio_recent_avg="-0.2"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="61"
Aroon_momentum_negative="39"
image_negative_thumbnail_id_1="133"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0043.jpeg"
image_negative_thumbnail_id_2="1151"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0184.jpeg"
image_neutral_thumbnail_id_1="578"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0021.jpeg"
image_neutral_thumbnail_id_2="554"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0045.jpeg"
image_positive_thumbnail_id_1="683"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0025.jpeg"
image_positive_thumbnail_id_2="980"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0142.jpeg"
image_professor_thumbnail_id_1="1181"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0015.jpeg"
image_professor_thumbnail_id_2="1194"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0028.jpeg"
